C-Terminal VWF Variants in von Willebrand Disease: Functional Insights from the D4-C6 Domains
The RPTH Journal (Research and Practice in Thrombosis and Haemostasis) shared an insightful post on LinkedIn:
”A small panel of VWF variants were investigated for expression and function – and how they might cause Von Willebrand Disease.
Golzar Mobayen and team reveal that the D4 and C-domains of VWF might play a role!
Other Authors: Sammy El-Mansi, Alain Chion, Tom Nightingale, and Tom McKinnon.”
Read the full article here.
The ”Probing rare von Willebrand disease–causing mutations in the D4 and C-domains of von Willebrand factor” study published by Golzar Mobayen et al. in the RPTH Journal, sheds light on the possible roles of vWF C-terminal D4-C6 domains in development of VWD.
Von Willebrand disease (VWD) arises from quantitative or qualitative deficiencies in von Willebrand factor (VWF), with a broad spectrum of genetic variants contributing to disease pathology.
However, mutations within the C-terminal D4-C6 domains of VWF remain under-characterized.
The findings demonstrate that variants in this region can significantly impair VWF expression and function.
Furthermore, the phenotypic impact varies depending on zygosity, with distinct differences observed between homozygous and heterozygous states.
These insights underscore the importance of the VWF C-terminal domains in maintaining normal hemostatic function.
All the latest scientific advancements on bleeding disorders featured in Hemostasis Today.
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025